03 · What You Need to Know
What a Research Pause Is Supposed to Accomplish
A Pause Is an Interim Protective Measure
Pausing research is not necessarily a final judgment that the study is unethical. It can be a temporary response to uncertainty.
OHRP guidance identifies suspension of new participant enrollment and suspension of research procedures in currently enrolled participants among the corrective actions that may be considered when an unanticipated problem reveals greater risk than previously recognized.
The purpose is to prevent additional exposure while investigators, ethics committees, sponsors, monitoring bodies, or regulators determine whether the study can safely and ethically continue.
Pausing Is Different From Stopping Permanently
The distinction matters.
Pause or suspension
A temporary interruption while a problem is investigated, safeguards are revised, or a decision about continuation is made.
Termination or stopping
A decision that the affected research will not continue in its current form, often because continuation can no longer be ethically or scientifically justified.
A pause preserves the possibility of resumption. Termination generally reflects a more definitive conclusion. The terminology and legal consequences can differ across oversight systems, so researchers should use the definitions applicable to their institution and study.
You Do Not Need Absolute Proof of Harm Before Considering a Pause
If researchers had to establish causality beyond doubt before interrupting exposure, participant protection could arrive too late.
OHRP defines “possibly related” in its unanticipated-problem framework as a reasonable possibility that an event may have been caused by the research. Its guidance recommends consideration of substantive corrective actions when unexpected information related or possibly related to participation suggests greater risk than previously recognized.
The threshold for pausing is therefore not necessarily certainty. It is whether the evidence and potential consequences make continued exposure difficult to justify while the question remains unresolved.
The More Serious the Potential Harm, the Less Reassuring Uncertainty Becomes
A weak signal concerning a trivial, reversible effect may reasonably lead to additional monitoring while research continues. The same degree of uncertainty about a potentially fatal or irreversible outcome may justify a more precautionary response.
This follows from the basic distinction between probability and magnitude. The possibility of severe harm can make waiting for additional cases ethically problematic even when the event appears uncommon.
Researchers should therefore consider very unlikely but potentially serious harms differently from equally unlikely trivial effects.
Pause When the Existing Safeguards May No Longer Be Adequate
A study was approved partly because specific protections were expected to manage its risks. New information may show that those protections are insufficient.
For example, monitoring intervals may be too long to detect a complication early. Existing exclusion criteria may fail to identify a newly recognized high-risk group. A data-security control may prove inadequate. An interview protocol may produce more severe distress than anticipated.
If researchers cannot immediately establish that existing protections remain adequate, a targeted pause can prevent additional exposure while safeguards are revised and reviewed.
Pause When You Need Time to Understand a Credible Pattern
Some safety signals emerge from aggregation rather than one dramatic event.
Several individually modest adverse events may collectively indicate that the procedure is more harmful than expected. A data monitoring committee may identify a trend. Participants may withdraw disproportionately after the same procedure.
OHRP's guidance recognizes unexpected frequency as part of determining whether events represent greater risk than previously known.
A pause can prevent the next cohort from being exposed while the pattern is investigated.
New Enrollment and Current Participation Are Separate Questions
A particularly important distinction is whether to pause new enrollment or interrupt procedures for people already enrolled.
OHRP lists both options separately.
Stopping recruitment may prevent new people from entering an uncertain situation while allowing current participants to continue procedures that remain in their best interests. Conversely, a newly recognized danger associated with a specific intervention may justify interrupting that procedure for current participants as well.
Watch Out
Do not assume that suspending everything is always the safest response. For some participants, abruptly stopping a research intervention, medication, monitoring schedule, or other procedure could itself create harm. The welfare of currently enrolled participants should be considered separately from whether new enrollment should continue.
A Pause Can Be Narrower Than the Entire Study
The problem may be confined to one component.
Suppose an optional biopsy creates a newly recognized risk while the main intervention remains adequately justified. Pausing the biopsy may protect participants without interrupting the entire study.
Likewise, a confidentiality concern might require pausing a particular data-transfer process rather than all participant activities. A safety concern affecting one dose level may not necessarily justify suspending every cohort.
The scope of the pause should match the source and reach of the uncertainty whenever participant protection permits.
New External Evidence Can Justify a Pause
A study does not need to generate its own adverse event before a pause becomes reasonable.
New information from another study, site, regulator, sponsor, or safety-monitoring body may materially change the known risk or expected benefit. OHRP guidance recognizes new information from the research itself or other sources as relevant to previous risk determinations.
If credible external evidence would make continued enrollment questionable, waiting for the same problem to occur locally would add little ethical wisdom.
New Consent Information Can Require an Enrollment Pause
Sometimes the study may remain potentially acceptable, but the consent information is no longer accurate enough for new participants to make an informed decision.
In guidance concerning NCI/CTEP-sponsored clinical trials, OHRP explains that when new or modified risk information requires changes to the description of reasonably foreseeable risks or discomforts in consent documents, new participants cannot be enrolled until revised consent materials and accompanying protocol changes are reviewed and approved by the IRB, except for changes necessary to eliminate apparent immediate hazards.
That guidance is specific to the context it addresses, but it illustrates an important principle: recruitment should not outrun materially changed information about what prospective participants are being asked to accept.
Scientific Futility Can Also Change the Case for Continuing
Safety is not the only reason continuation can become ethically questionable.
If convincing evidence shows that the study cannot achieve its scientific objective or that the primary question has already been definitively answered, continued participant exposure may lose its justification.
The Declaration of Helsinki requires researchers to assess whether to continue, modify, or immediately stop research not only when risks and burdens outweigh potential benefits but also when there is conclusive proof of definitive outcomes.
A temporary pause may sometimes be appropriate while such evidence is evaluated, although definitive findings may ultimately support stopping rather than resumption.
A Pause Should Have a Question It Is Trying to Answer
“Pause until further notice” is not a particularly informative safety strategy.
A useful pause should identify why exposure has been interrupted and what must be resolved before a decision can be made. Questions might include:
- Is the adverse event causally related to the intervention?
- Is its frequency higher than previously estimated?
- Can a high-risk subgroup be identified?
- Would additional monitoring detect the problem early enough?
- Can the procedure be modified to reduce the risk?
- Does the revised risk remain justified by potential benefits and scientific value?
The answers provide criteria for modification, resumption, or termination.
Pausing Should Trigger Investigation, Not Administrative Limbo
A pause protects participants only if the underlying problem is actively evaluated.
Researchers may need to review accumulated data, obtain independent clinical or statistical assessment, consult a data and safety monitoring body, investigate protocol implementation, review external evidence, or propose amendments.
The ethics committee or other oversight body may need sufficient information to determine whether the original approval criteria remain satisfied.
Current Participants May Need to Be Told About the Pause
A pause can directly affect participants' appointments, treatment, monitoring, expectations, and decisions.
SACHRP recommends transparency with participants when research is suspended or terminated and notes that notification should be calibrated to the issue and participant status. New information affecting continued participation may need to be communicated to current participants.
Researchers should explain what has changed, what the pause means for the participant, what procedures will or will not continue, and what happens next, as appropriate to the circumstances.
Resuming Research Requires More Than the Passage of Time
A pause should end because the ethical problem has been sufficiently resolved, not because everyone has become accustomed to waiting.
Before resumption, researchers and the relevant oversight bodies should determine whether the evidence supports continuation, whether safeguards or eligibility criteria require modification, whether consent information has been updated, and whether participants should be re-consented.
SACHRP notes that when research procedures resume after suspension or termination decisions, continuing participants should be informed of relevant changes and consented to revised research where necessary.
A Pause Can End in Several Different Ways
Resume unchanged
Investigation shows that the signal does not materially change the known risk and the original safeguards remain adequate.
Resume with modifications
Additional monitoring, revised eligibility, procedural changes, or other safeguards restore an acceptable balance.
Resume only part of the study
Safe components continue while a problematic intervention or procedure remains suspended or is removed.
Do not resume
The revised evidence shows that the research can no longer be ethically or scientifically justified.
The last possibility leads to the separate question of when research should be stopped because participants may be harmed.
